The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04121221
Recruitment Status : Completed
First Posted : October 9, 2019
Last Update Posted : December 1, 2023
Sponsor:
Information provided by (Responsible Party):
Mapi Pharma Ltd.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks

Condition or disease Intervention/treatment Phase
Multiple Sclerosis, Relapsing-Remitting Drug: GA Depot Other: Placebo Phase 3

Detailed Description:

A total of 1000 subjects are planned to be randomized into this study to receive treatment with GA Depot or with matching placebo.

During the placebo controlled period (PC period, the first 52 weeks of the study immediately after randomization) subjects will receive either 40mg of GA Depot or matching placebo, IM, once every 4 weeks, for a total of 13 times.

Subjects who complete the PC period of the study will be offered to continue into the open label period (OL period) for an additional 52 weeks, in which all subjects will receive 40mg of GA Depot IM once every 4 weeks.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1016 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

During the placebo controlled period subjects will receive either 40mg of GA Depot or matching placebo, IM, once every 4 weeks, for a total of 13 times.

Subjects who complete the PC period of the study will be offered to continue into the open label period for an additional 52 weeks, in which all subjects will receive 40mg of GA Depot IM once every 4 weeks.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Acetate, Once Monthly Compared to Placebo
Actual Study Start Date : September 19, 2019
Actual Primary Completion Date : June 13, 2023
Actual Study Completion Date : June 13, 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: GA Depot
Monthly IM injection
 Drug: GA Depot
Long acting intramuscular injection of glatiramer acetate, once every 4 weeks
Placebo Comparator: Placebo
Monthly IM injection
 Other: Placebo
IM injection once every 4 weeks


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Annualized Relapse Rate (ARR) [ Time Frame: 52 weeks ]
    Annualized Relapse Rate (ARR) will be derived from the total number of confirmed relapses.


Secondary Outcome Measures :
  1. Changes in brain MRI (number of T1 lesions) [ Time Frame: 52 weeks ]
    Cumulative number of new enhancing lesions on T1-weighted images as compared to baseline.

  2. Changes in brain MRI (number of T2 lesions) [ Time Frame: 52 weeks ]
    Cumulative number of new or newly enlarging hyperintense T2 lesions as compared to baseline.

  3. Hyperintense T2-lesion volume change [ Time Frame: 52 weeks ]
    Change from baseline to Week 52 in hyperintense T2-lesion volume.

  4. Enhancing T1-lesion volume change [ Time Frame: 52 weeks ]
    Change from baseline to Week 52 in enhancing T1-lesion volume.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Adult subjects between 18-55 years of age, inclusive.
  2. Subjects able to provide signed written informed consent.
  3. Subjects must be willing and able to comply with the protocol requirements for the duration of the study.
  4. MS diagnosis fulfilling the 2017 McDonald Criteria.
  5. Subjects should be ambulatory with an EDSS score of 0-5.5 at screening and baseline visits. EDSS score will be determined by a separate, blinded trained EDSS rater.
  6. Subjects should be relapse free and neurologically stable from one month before screening visit and from screening visit to baseline visit.
  7. No systemic corticosteroid treatment or ACTH within one month prior to screening visit.

  8. Subjects must have experienced at least one of the following:

    i. At least one documented relapse in the 12 months prior to screening. ii. At least two documented relapses in the 24 months prior to screening. iii. One documented relapse between 12 and 24 months prior to screening, with at least one documented T1-Gd enhancing lesion in MRI performed within 0-12 months before screening.

  9. Women capable of child bearing must have a negative urine pregnancy test at screening and baseline visit and use an adequate contraceptive method throughout the study.

Exclusion criteria:

  1. Use of experimental / investigational drug, and / or participation in drug clinical studies within the 6 months prior to screening.
  2. Any off-label drug use for MS treatment such as high dose simvastatin and biotin within 6 months prior to screening.
  3. Previous use of immunosuppressant including Mitoxantrone, Alemtuzumab, Cladribine or any other cytotoxic agent within 5 years.
  4. Previous use of Natalizumab or any anti-B cell agent within 9 months prior to screening.
  5. Previous use of Fingolimod or any other sphingosine-1-phosphate receptor modulator, Dimethyl Fumarate, Diroximel Fumarate (DRF), or Monomethyl fumarate within 2 months prior to screening. Subjects will be excluded if they do not have a lymphocyte count of above 1,000/mm3 at screening.
  6. Previous use of Teriflunomide within 12 months if no accelerated elimination procedure was used.
  7. Previous treatment with immunomodulators (including IFNβ 1a and 1b, and IV Immunoglobulin (IVIg) within 2 months prior to screening.
  8. Previous use of GA or any other glatiramoid.
  9. Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid treatment within 6 months prior to screening visit.
  10. Previous total body irradiation or total lymphoid irradiation.
  11. Previous stem-cell treatment, autologous bone marrow transplantation or allogeneic bone marrow transplantation.
  12. Subjects with a clinically significant or unstable medical, psychiatric, or surgical conditions that would preclude safe and complete study participation, as determined by medical history, physical exams, ECG and/or abnormal laboratory tests; and or subjects with an increased risk of serious Covid-19 related morbidity. Such conditions may include hepatic, renal or metabolic diseases, systemic disease, acute infection, current malignancy, or recent history (5 years) of malignancy, major psychiatric disorder, history of drug and/or alcohol abuse and allergies that could be detrimental according to the investigator's judgment.
  13. Subjects who have >10 T1-Gd enhancing lesions at screening.
  14. A known history of sensitivity to Gadolinium.
  15. Inability to successfully undergo MRI scanning.
  16. Pregnant or breast-feeding women.
  17. Abnormal renal function.
  18. Abnormal liver function.
  19. History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study article (e.g., GA, Polyglactin, PVA).
  20. Positive testing or a history of positive testing for syphilis, HIV, hepatitis, or tuberculosis.
  21. Known or suspected history of drug or alcohol abuse.
  22. Subjects diagnosed with any systemic autoimmune disease (other than MS) that may impact the CNS with MS like lesions such as Sarcoidosis, Sjögren's syndrome, Systemic Lupus Erythematosus (SLE), Lyme disease, Antiphospholipid antibodies (APLA) syndrome, etc. Subjects with stable local/organ autoimmune disease such as psoriasis, cutaneous lupus erythematosus, thyroiditis (Hashimoto's, Grave's) etc. may be considered eligible upon the investigator's discretion.
  23. Any CNS disorder other than MS that may jeopardize the subject's participation in the study.
  24. Subjects with uncontrolled diabetes.
  25. Subjects with clotting disorders or receiving treatment with anticoagulants.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04121221


Locations
Show Show 112 study locations
Sponsors and Collaborators
Mapi Pharma Ltd.
Investigators
Layout table for investigator information
Study Director: Laura Popper, MD Mapi Pharma Ltd.
Principal Investigator: Aaron E. Miller, Prof. MD Mount Sinai School of Medicine, New York, US
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Mapi Pharma Ltd.
ClinicalTrials.gov Identifier: NCT04121221    
Other Study ID Numbers: Mapi GA Depot Phase III - 001
First Posted: October 9, 2019    Key Record Dates
Last Update Posted: December 1, 2023
Last Verified: November 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Mapi Pharma Ltd.:
Multiple Sclerosis
RMS
GA Depot
Multiple Sclerosis, Relapsing-Remitting
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
 Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases